Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

47.27USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$47.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
298,459
52-wk High
$61.24
52-wk Low
$13.50

Select another date:

Thu, Mar 8 2018

BRIEF-Crispr Therapeutics Qtrly ‍​collaboration Revenue $32.3 Mln

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

BRIEF-CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs

* CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs

BRIEF-Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​

* Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​ Source text: (http://bit.ly/2jeQFaT) Further company coverage:

BRIEF-CRISPR Therapeutics announces third quarter results

* CRISPR Therapeutics announces third quarter 2017 financial results and provides business update

Select another date: